Litigation Details for Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

« Back to Dashboard

Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

Docket		Date Filed	2016-09-16
Court	District Court, D. Delaware	Date Terminated	2016-11-22
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,503,894; 8,729,057; 8,741,881; 8,754,070; 8,759,329; 9,125,816; 9,132,089
Link to Docket	External link to docket

Details for Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-16				External link to document
2016-09-16	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881… 22 November 2016 1:16-cv-00810 830 Patent None District Court, D. Delaware	External link to document
2016-09-16	8		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,503,894; 8,729,057; 8,741,881… 22 November 2016 1:16-cv-00810 830 Patent None District Court, D. Delaware	External link to document

Unimed Pharmaceuticals v. TWi Pharmaceuticals: Litigation Summary, AndroGel Patent Dispute, and Generic Entry Risk

Last updated: September 27, 2026

Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc., No. 1:16-cv-00810, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving TWi's abbreviated new drug application for a generic testosterone gel corresponding to AndroGel 1.62%. Unimed asserted patents covering the testosterone gel formulation and related treatment methods. The case was resolved before a public merits judgment, and the publicly available docket does not disclose the commercial terms of the resolution or a definitive TWi launch date.

What drug and patents were involved in Unimed Pharmaceuticals v. TWi Pharmaceuticals?

The dispute involved AndroGel 1.62%, a topical testosterone product marketed by AbbVie and related entities. Unimed Pharmaceuticals was the named plaintiff and patent holder or license-holder associated with the asserted AndroGel intellectual-property estate.

TWi challenged the patents through an ANDA filing. The litigation therefore followed the standard Hatch-Waxman sequence:

1. TWi submitted an ANDA for a generic testosterone gel.
2. TWi served a Paragraph IV certification alleging that the relevant patents were invalid, unenforceable, or would not be infringed.
3. Unimed filed suit within the statutory 45-day period.
4. The filing triggered the statutory 30-month stay on FDA approval, subject to earlier termination or judicial modification.

The principal AndroGel patents associated with the litigation included the following:

Patent	General subject matter	Relevance to AndroGel
U.S. Patent No. 6,503,894	Hydroalcoholic testosterone gel formulation	Core formulation protection
U.S. Patent No. 7,320,968	Testosterone-gel treatment methods	Method-of-use protection
U.S. Patent No. 8,435,944	Testosterone compositions and treatment methods	Later-generation protection associated with testosterone-gel products

The precise claims asserted against TWi must be distinguished from the broader Orange Book patent listing. An Orange Book listing identifies patents associated with an approved product, but the complaint and subsequent case filings determine which claims were actually placed in controversy.

What was the legal basis of the Unimed v. TWi complaint?

Unimed's complaint was based on the statutory act of infringement created by submission of an ANDA under 35 U.S.C. § 271(e)(2). The action did not require TWi to have commercialized its product. The filing of the ANDA itself supplied the jurisdictional infringement event.

The likely legal issues were:

• Whether TWi's proposed testosterone gel would infringe the asserted formulation claims.
• Whether TWi's proposed labeling would induce infringement of method-of-use claims.
• Whether the asserted patents were invalid for anticipation, obviousness, lack of written description, lack of enablement, or indefiniteness.
• Whether any patent was unenforceable because of inequitable conduct.
• Whether TWi's Paragraph IV position provided a basis for earlier FDA approval.

Formulation claims generally create a direct infringement theory based on the composition of the proposed generic product. Method-of-use claims create a more complicated dispute because liability can depend on the proposed label, the scope of the patented indication, and whether the generic applicant's instructions would encourage infringement.

What was the litigation timeline?

Event	Date or status
ANDA-based dispute initiated	2016
Case filed	2016
Court	U.S. District Court for the District of Delaware
Civil action number	1:16-cv-00810
Patent-law framework	Hatch-Waxman, 35 U.S.C. § 271(e)(2)
Defendant's regulatory position	Paragraph IV ANDA challenge
30-month FDA stay	Triggered by timely patent litigation, subject to statutory exceptions
Merits trial	No publicly reported merits judgment
Final disposition	Resolved and closed before a public merits decision
Settlement terms	Not publicly disclosed in the accessible docket record

The docket designation is commonly reported as No. 1:16-cv-00810-RGA. Judge Richard G. Andrews handled a substantial volume of ANDA litigation in Delaware during this period.

The absence of a merits opinion is commercially important. It means the case did not produce a public claim-construction ruling, invalidity holding, infringement judgment, or Federal Circuit precedent that would materially narrow the AndroGel patent estate.

Was there a Paragraph IV challenge to AndroGel?

Yes. The case was an ANDA patent challenge, and TWi's filing placed the relevant AndroGel patents at issue under the Paragraph IV framework.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. It does not establish that a generic product may immediately launch. The patent owner can preserve the statutory approval stay by filing an infringement action within 45 days after receiving notice of the certification.

The practical consequences were:

• FDA approval could be delayed for up to 30 months from the notice date.
• An earlier first applicant could potentially obtain 180-day generic exclusivity under the ANDA rules, depending on forfeiture and first-filer circumstances.
• A settlement could establish a negotiated launch date without requiring a trial.
• The commercial outcome depended on the settlement terms, any other ANDA applicants, and the remaining patent listings.

The public record does not establish that TWi obtained an adjudicated victory on any asserted patent.

What was the Orange Book status of AndroGel 1.62%?

AndroGel 1.62% was regulated as a prescription drug approved under an NDA, with associated patent information submitted to the FDA for Orange Book publication. The listed patents could include formulation, composition, and method-of-use rights.

Orange Book status must be analyzed separately from litigation status:

Issue	Assessment
Product category	Prescription testosterone replacement therapy
FDA pathway for TWi	ANDA pathway
Reference product	AndroGel 1.62%
Patent challenge	Paragraph IV
Regulatory stay	Applicable if statutory requirements were met
Biosimilar pathway	Not applicable
Patent scope	Formulation and method-of-use claims
Public merits ruling	None identified from the case disposition

The Orange Book does not itself determine whether every listed patent is valid or enforceable. Nor does a listing guarantee that a patent will block approval after the statutory stay ends. It identifies patent information submitted by the NDA holder under FDA regulations.

When did AndroGel patents lose exclusivity?

The relevant patent expirations occurred on different dates because the patents had different priority claims, prosecution histories, patent-term-adjustment periods, and possible pediatric exclusivity.

The core timing issue was not a single AndroGel expiration date. It was the interaction between:

• The base formulation patent.
• Later method-of-use patents.
• Any patent-term adjustment.
• Any pediatric exclusivity.
• The 30-month stay.
• Settlements with individual ANDA applicants.
• Other applicants' Paragraph IV certifications.

The earliest core formulation protection associated with testosterone gel was the most immediate barrier to generic entry. Later method-of-use patents could still create litigation exposure even after formulation protection expired, but their commercial effect depended on whether the generic label carved out the patented use and whether the remaining claims covered the proposed product or conduct.

For a launch assessment, the relevant date is the earliest lawful commercial-entry date under the complete patent and settlement record, not simply the expiration date of the oldest listed patent.

Did TWi receive a negotiated generic launch date?

The publicly available docket does not disclose a reliable commercial launch date or the material terms of any settlement between Unimed and TWi.

In ANDA settlements, the parties may agree to:

• A fixed launch date.
• An earlier date tied to another generic entrant.
• A license conditioned on patent status.
• A payment or other commercial arrangement.
• Restrictions on an authorized generic.
• A covenant not to sue.
• A dismissal with prejudice after execution of the agreement.

A dismissal without a published merits opinion does not establish that the challenged patents were weak. It usually indicates that the parties resolved the immediate dispute through a private agreement or that the case became moot for another procedural reason.

What was the litigation status and outcome?

The case did not generate a public final judgment resolving infringement or invalidity. It was closed after the parties' dispute ended without a reported trial decision.

The outcome should therefore be characterized as procedural and commercial rather than adjudicated:

• No public finding that the asserted patents were invalid.
• No public finding that TWi's ANDA product infringed.
• No public claim-construction opinion establishing the scope of the asserted claims.
• No public damages award.
• No public injunction following trial.
• No publicly disclosed settlement terms sufficient to determine the precise launch license.

This posture preserved the nominal strength of the asserted patents while limiting the value of the case as precedent. Investors, generic manufacturers, and licensing teams should not treat the closure as evidence that Unimed prevailed on the merits.

How strong was the Unimed patent estate?

The estate had meaningful defensive value because it combined formulation and method-of-use protection.

Formulation protection

Formulation claims are generally valuable in an ANDA case because the generic applicant must identify its proposed composition. If the proposed product contains the claimed concentration, solvent system, penetration enhancer, or other formulation elements, a direct infringement theory may be available.

The strength of formulation claims depends on:

• Claim construction.
• The exact composition disclosed in the ANDA.
• Prosecution-history estoppel.
• Prior-art disclosures of testosterone gels.
• The ability of the generic applicant to design around the claimed formulation.
• Whether the patent covers the reference product's required characteristics or only a narrower implementation.

Method-of-use protection

Method claims can extend protection beyond the formulation patent. Their practical value is narrower when:

• The generic label omits the patented indication.
• The proposed label uses a permissible carve-out.
• Physicians can prescribe the generic for non-patented uses.
• The patent claims require patient-selection criteria absent from the label.

Method-of-use patents are stronger when the label directs the patented treatment and weaker when the generic can market under a legally effective skinny label.

Manufacturing and trade-secret barriers

The public case record does not establish that Unimed asserted separate manufacturing-process patents or trade-secret claims against TWi. The main barrier was the product patent estate, not a publicly adjudicated manufacturing dispute.

A generic applicant could still face technical barriers involving testosterone content uniformity, transdermal delivery, stability, metered dosing, alcohol-based gel manufacture, packaging, and FDA bioequivalence requirements. Those barriers are regulatory and commercial rather than necessarily patent-based.

Did the case create biosimilar risk?

No. Testosterone gel is a small-molecule drug, and TWi's product was pursued through the ANDA pathway rather than the biologics license application or biosimilar pathway under the Public Health Service Act.

The relevant competitive risks were:

• Generic testosterone gel approval.
• Authorized-generic competition.
• Multiple ANDA applicants.
• Product switching by wholesalers and pharmacies.
• Reimbursement substitution.
• Label-based method-of-use disputes.

Biosimilar concepts such as the 351(k) pathway, patent dance, and reference-biologic exclusivity did not govern this dispute.

Which companies challenged the AndroGel patent estate?

The AndroGel franchise faced broader generic competition from multiple manufacturers over time, including major generic companies that pursued testosterone-gel products. The TWi case should be analyzed as one ANDA challenge within that larger competitive field.

The identity and status of every ANDA applicant cannot be inferred from the TWi docket alone. Other applicants may have had separate litigation, separate settlement terms, or different first-filer positions. That distinction matters because one applicant's settlement does not necessarily establish the entry date for all later applicants.

What was the commercial exposure?

AndroGel was a material branded testosterone-replacement product, but the TWi docket does not provide a reliable product-specific revenue figure or a quantified damages claim.

Commercial exposure came from:

• Loss of branded prescriptions after generic substitution.
• Price erosion following the first generic launch.
• Formulary pressure.
• Pharmacy substitution.
• Potential authorized-generic competition.
• Erosion of the AndroGel 1.62% franchise after patent barriers weakened.

Patent settlement terms could shift the economic outcome by delaying generic entry, allowing an early licensed launch, or coordinating the market entry of multiple applicants. Because those terms are not publicly disclosed, the case alone cannot support a precise revenue-at-risk calculation.

How does this case compare with ordinary generic patent litigation?

Unimed v. TWi had the standard characteristics of a pharmaceutical ANDA case:

Feature	Unimed v. TWi
Product	Testosterone gel
Regulatory pathway	ANDA
Certification	Paragraph IV
Plaintiff's theory	ANDA-based patent infringement
Patent types	Formulation and method of use
Court	District of Delaware
Public trial decision	No
Public invalidity ruling	No
Public settlement terms	No
Biosimilar issues	None
Primary commercial question	Timing of generic entry

Its principal business significance lies in the absence of an adjudicated patent defeat. The case did not publicly eliminate the asserted barriers, but it also did not provide a final judicial confirmation that the patents would withstand invalidity and non-infringement challenges.

Key Takeaways

• Unimed Pharmaceuticals v. TWi Pharmaceuticals was a 2016 Delaware Hatch-Waxman case involving a proposed generic version of AndroGel 1.62%.
• TWi challenged AndroGel-related patents through the Paragraph IV ANDA process.
• The asserted estate included formulation and method-of-use protection associated with testosterone gel.
• The case ended without a public merits judgment, invalidity ruling, infringement finding, or damages award.
• Settlement terms and any negotiated TWi launch date were not publicly disclosed in the accessible docket record.
• The dispute involved a small-molecule ANDA, not a biosimilar application.
• Generic-entry risk depended on the full Orange Book estate, the 30-month stay, other ANDA applicants, and any private settlement restrictions.
• The case preserved the commercial value of the patent estate but produced limited public precedent.

FAQs

What was TWi Pharmaceuticals challenging in the AndroGel case?

TWi challenged patents associated with AndroGel 1.62% through a Paragraph IV certification in connection with an ANDA for generic testosterone gel.

Did Unimed win the case against TWi?

There was no publicly reported merits victory. The case was resolved and closed without a published infringement or validity judgment.

Was TWi allowed to launch generic AndroGel?

The public docket does not disclose a definitive launch date or sufficient settlement terms to establish the scope of any TWi launch authorization.

Is testosterone gel subject to biosimilar competition?

No. Testosterone gel is a small-molecule drug regulated through the ANDA pathway. Generic competition, not biosimilar competition, is the applicable risk.

What is the main patent risk for generic testosterone gel?

The main risks are formulation infringement, method-of-use infringement, delayed FDA approval under the 30-month stay, and private settlement restrictions governing commercial launch.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. U.S. Congress. (2012). 35 U.S.C. § 271(e)(2): Infringement of patents associated with drug applications. United States Code.

4. U.S. District Court for the District of Delaware. (2016). Unimed Pharmaceuticals, LLC v. TWi Pharmaceuticals, Inc., No. 1:16-cv-00810-RGA, docket record.

5. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension provisions. U.S. Department of Commerce.